As CRISPR gene editing technology has advanced in the last few years, the number of genetically modified animals made with this system has steadily increased. Some are very interesting and useful for science. At the same time especially when they are little, they can be very cute. A nickname is going around for these GM […]
CRISPR critters: Cute pics of Cas9 gene edited animals Read More »
One of the many interesting ways in which “stem cells” are named in different languages around the world is “mother cells”. For example, in Spanish, you can learn more about these “mother cells” here in ¿Qué son las células madre? On Mother’s Day it is worth thinking about where the stem cell field stands at this
Stem cells on Mother’s Day, clinical trials, and more Read More »
The list of stem cell journals seems to grow longer every day. In fact, the list is so long and some of the names kind of funny that it inspires coming up with a slew of satirical and nonsensical stem cell journals. I’m betting that some of these (the ones listed first) may be thought up
The nonsensical list of stem cell journals Read More »
It’s hard to even imagine the world of investigative medicine without the wonderful resource of Clinicaltrials.gov, the global hub for clinical trial listings. I recently interviewed the Director of Clinicaltrials.gov, Dr. Deborah Zarin here, which is a fascinating read. As great as Clinicaltrials.gov is as a resource, unfortunately it faces a new, rapidly growing problem that is a serious
Clinicaltrials.gov Mission At Risk From Proliferating For-Profit Trials Read More »
This post is the first in a series about the Clinicaltrials.gov website. This piece is an interview the Director, Dr. Deborah Zarin. I want to thank her for taking the time to answer my questions. Later, I will post Part 2 in which I discuss my concerns about the trend of for-profit stem cell clinic trials
Interview with Clinicaltrials.gov Director Deborah Zarin Read More »
I invited Neuralstem CEO, Richard Garr, to do a Q&A interview and he kindly accepted. The interview provides some novel insights into this major biotech in the stem cell sector. 1. How is Neuralstem doing today? What programs are underway that you find particularly exciting? Garr: Neuralstem is moving on all cylinders these days on
Interview with Neuralstem CEO Richard Garr Read More »
This is Part 2 of my interview with ALS and stem cell advocate, Ted Harada. You can read Part 1 of my talk with Ted on where things stand today with ALS, the FDA, and the Ice Bucket Challenge. What’s your opinion of the “Right To Try” law in Colorado and the concept more generally?
Interview with Ted Harada Part 2: Right To Try, Neuralstem, and How He’s Doing Read More »
Ted Harada is a wonderful patient advocate for the stem cell field and for the development of safe and effective stem cell products to treat ALS. Ted has ALS and received stem cell-based treatments for it with surprising, very encouraging results. The Harada family is pictured at left with Ted, his wife Michelle as well as
Ted Harada Interview Part 1: Stem Cells for ALS, More Read More »
Is Neuralstem flirting with noncompliance via a Right To Try Law in Colorado? Colorado is an independent-minded state. For example, it is one of only a few states including Washington State with legalized marijuana use. More recently, Colorado passed a new law supported by the ultra-conservative Goldwater Institute, the so-called Right To Try Law. This law
Neuralstem flirting with noncompliance via Right To Try Law? Read More »
Dr. Charles Cox at the University of Texas (UT) Health Science Center at Houston is starting a new stem cell-based clinical trial for the treatment of young children with cerebral palsy (CP). There is an urgent need for the development of new treatments for CP. You can learn more about the details of this specific
Interview with Dr. Charles Cox on New Stem Cell Trial for Cerebral Palsy Read More »